Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Kidney Case Conference: How I Treat
You have accessRestricted Access

Hypernatremia

Qi Qian
CJASN March 2019, 14 (3) 432-434; DOI: https://doi.org/10.2215/CJN.12141018
Qi Qian
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic School of Medicine, Rochester, Minnesota
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • hypernatremia
  • water regulation
  • sodium regulation
  • pathophysiology
  • diagnosis
  • treatment
  • Sodium
  • Potassium
  • Dehydration
  • diabetes insipidus
  • Ions
  • Acids
  • Noncarboxylic

Introduction

Hypernatremia, serum sodium concentration ([Na+]) of >145 mmol/L, represents a state of total body water deficiency absolute or relative to total body Na+ and potassium. It can result from (1) water loss (e.g., diabetes insipidus [DI]), (2) hypotonic fluid loss (osmotic diarrhea), or (3) hypertonic fluid gain (Na+-containing fluids). Hypernatremia often occurs in pediatric, geriatric, and critically ill patients. Hypernatremia induces diverse effects in multiple organ systems, with short-term mortality of approximately 50%–60%. Even mild hypernatremia ([Na+]<150 mEq/L) confers a 30-day mortality of >20%. We dissect the underlying pathophysiology of two patients to help develop a treatment plan.

Patient 1

A 79-year-old nursing home resident with hypertension and prior strokes was admitted for decrease in mental status over 5 days. On evaluation, she was somnolent, temperature was 39.5°C, BP was 140/60 mm Hg, pulse was 102/min, and respiratory rate was 24/min (baseline weight of 56 kg). Her breath sounds were reduced; chest x-ray revealed a lobar pneumonia. Laboratory studies showed serum [Na+] of 170 mEq/L, serum creatinine of 1.5 mg/dl, and urine osmolality of 780 mOsm/kg. She was given 1 L of saline en route.

Patient 2

A 35-year-old woman with bipolar disorder and past suicide attempts presented with polyuria and frequent bedwetting. She had been on lithium carbonate (600 mg twice daily) for 7 months. Recently, she had a fasting serum [Na+] of 147 mEq/L and serum lithium level of 0.8 (therapeutic range: approximately 0.6–1.2) mmol/L. Her examination was unremarkable: BP was 100/58 mm Hg, and heart rate was 90/min. Serum [Na+] was 144 mEq/L, and creatinine was 0.8 mg/dl; 24-hour urine volume was 5.7 L, and osmolality was 160 mOsm/kg.

Serum [Na+] Regulation and Pathophysiology of Hyperosmolality

Under physiologic conditions, normonatremia is achieved through thirst-driven water intake and arginine vasopressin (AVP)–mediated water conservation in the kidney. Although the kidney has historically been considered “The Organ” with capacity to regulate Na+ balance, recent studies have shown tissue (mainly skin) storage pools of Na+ that can be mobilized in and out of extracellular fluids (ECFs) and that likely participate in Na+ homeostasis.

Hypernatremia increases ECF osmolality and tonicity, causing water efflux and generating a cell shrinkage force (Figure 1). The latter triggers an adaptive regulatory volume increase, which imports ionic osmolytes (Na+, K+, and Cl−) within minutes, with water following suit. This countershrinkage response is, however, a short-term fix, because the ions are highly cytotoxic. Fortunately, the osmostress evokes another set of responses via tonicity-responsive enhancer binding protein (TonEBP), a ubiquitously expressed transcriptional factor. TonEBP drives cellular accumulation of less toxic organic osmolytes (mainly myoinositol, sorbitol, betaine, and taurine) and proadaptive chaperon proteins. These molecules, within hours to days, replace the ionic osmolytes. The adapted cells are, however, far from normal. Molecular crowding and multiple functions exerted by the organic osmolytes can disrupt intracellular milieu. Moreover, through its transcriptional activity, TonEBP can increase cellular reactive oxygen species and cytokines. Thus, barring correction of hypernatremia, ongoing cell damage persists.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Cellular adaptation and relations of serum and urine osmolality. (A) Hypernatremia causes a rapid osmotic water efflux, which activates regulatory volume increase. The latter counters the cell shrinkage force by initially gathering ionic osmolytes (within minutes) and subsequently, through a transcriptional process, replacing the ionic osmolytes with more compatible organic osmolytes (within hours to days). The accumulation of intracellular organic osmolytes, although less toxic, can cause multiple cellular dysfunctions as evidenced by continued DNA breakdown and oxidative stress. Tissue can buffer extracellular fluid Na+ and constitutes another potential aspect of Na+ concentration regulation. Until hyperosmolality is corrected, these abnormalities persist. (B) The relationship between plasma and urine osmolality during the (a) genesis, (b) adaptation, and (c) correction (resolution) phases of a hypernatremia episode is depicted. Our first patient had an adequate kidney response to antidiuretic hormone, arginine vasopressin. Her urine became concentrated (solid yellow line) before the elevation of serum osmolality. During resolution (fluid administration), the serum osmolality returned to normal before urine dilution. The dotted yellow line represents our second patient. Her urine concentration would be minimally increased despite elevation of serum osmolality, consistent with lithium-induced nephrogenic diabetes insipidus.

During hypernatremia correction, downward shift of the ECF tonicity (by hypotonic fluid administration) causes water influx into the cell, creating a cell-swelling force, which activates regulatory volume decrease. During this process, excess osmolytes are expelled, and cells return to their normal state. Rapid correction (abrupt fall in ECF tonicity) can outpace this regulatory volume decrease, causing cell swelling and irreversible damage.

Lithium-Induced Nephrogenic DI

Lithium is the most common cause of acquired nephrogenic DI. It is believed that lithium competes with Na+ and Mg2+ in their binding to several proteins and exerts mainly inhibitory effects. Glycogen synthase kinase-3β (GSK3β), an Mg2+-dependent lithium-sensitive enzyme, represents a major lithium-affected pathway. In the kidney, lithium-mediated GSK3β inhibition (1) moderates adenylyl cyclase–mediated cAMP production and (2) releases the inhibitory effects of GSK3β on cyclooxygenase-2, leading to unrestrained prostaglandins (PG) generation. Both effects impair AVP-mediated water transport, inducing a state of AVP resistance and nephrogenic DI. Lithium also interferes with tubular Na+ absorption and blunts aldosterone responsiveness. Excess tubular fluid Na+ creates osmostress and constricts afferent arterioles, risking tubular injury and glomerular ischemia. Long-term lithium exposure and intracellular lithium accumulation have been associated with kidney tubulointerstitial scarring, microcyst formation, CKD, and occasionally, end stage kidney failure.

Diagnosis and Treatment

History and physical examination typically reveal the etiology and duration of hypernatremia. In patient 1, increased insensible water loss (pyrexia), impaired thirst, and possible lack of water provision resulted in hypernatremia. Patient 2 (lithium exposure, dilute urine, and high-normal [Na+]) is consistent with lithium-induced nephrogenic DI.

Water deprivation study (1) is the test of choice for diagnosing DI. It entails water deprivation (to induce hypernatremia, [Na+] approximately 150 mEq/L) followed by vasopressin challenge. Serum [Na+] and urine concentrations are serially monitored. Increase in urine concentration with the vasopressin challenge is consistent with central DI. If urine remains dilute, nephrogenic DI is present. Diagnostic dilemma often arises in patients with partial DI (1). The study should be conducted in a controlled setting to prevent complications, including symptomatic dehydration and postvasopressin acute water intoxication. Copeptin, a surrogate marker of circulating AVP, has emerged as a diagnostic test for differentiating polyuria due to primary polydipsia and central DI (2). For nephrogenic DI (patient 2), a baseline (without water deprivation) serum copeptin can confirm the diagnosis (3).

Hypernatremia for <48 hours is considered acute; [Na+] correction rate can be up to 1 mEq/L per hour. Hypernatremia of 2 days or unknown duration is considered chronic and should be corrected gradually, <0.5 mEq/L per hour (approximately 10 mEq/L per day). There have been newer corroborating observations showing a higher mortality rate with (1) [Na+] correction >0.5 mEq/L per hour (compared with approximately 0.35–0.45 mEq/L per hour) in neonates with [Na+]>150 mEq/L (4) and (2) slow correction of <0.25 mEq/L per hour in adults with [Na+]>155 mEq/L (5). Additional studies have also shown a negative effect of slow [Na+] correction (>3–4 days) on mental status recovery (6) and survival (6,7). These observations are consistent with growing knowledge of an asymmetric time course in the genesis and dissipation of cellular osmolytes. Interventional studies would be ideal to further clarify the optimal [Na+] correction rate.

For patients with hypovolemia, volume correction with isotonic fluids takes precedence. Urine [Na+] is unreliable as a volume indicator, because it can be elevated due to dehydration natriuresis (8). Water repletion should commence after volume stabilization. The amount of water administration can be estimated initially by determining the total body water deficit: body weight (kilograms) ×(0.5 for women; 0.6 for men) × (serum [Na+]/140–1). Water may be given orally if tolerated. Of importance, existing formulas perform poorly in predicting the expected [Na+] change with a given volume of water administration. It is, therefore, imperative to monitor serum [Na+], often every 2 hours initially, to control the speed of correction.

For patient 1, her water deficit was approximately 6 L [56×0.5×(170/140–1)]. Assuming (1) insensible loss to be approximately 1.2 L/d (600 ml skin and 600 ml respiratory loss) and (2) urine and stool output to be zero, to correct her [Na+] to approximately 142–145 mEq/L (from 170) in 3 days, she would need approximately 9.6 L of water (6 L deficit +3.6 L insensible loss). We thus initiated 5% dextrose water infusion at 130 ml/h (3.12 L/d). Note that these estimates do not include her future urine/stool output or potential tissue Na+ mobilization, and they serve only as a starting reference. Her [Na+] was monitored closely, and the infusion rate was adjusted to keep the correction at approximately 0.4 mEq/L per hour. She reached normonatremia in 3 days and regained mental lucidity.

Treatment for DI is on the basis of etiology; desmopressin is effective for central DI (1). For lithium-induced nephrogenic DI (patient 2), options include (1) dosing lithium once daily to minimize exposure, (2) adding amiloride to impede distal tubular lithium uptake via epithelial sodium channels, (3) adding thiazide to augment (AVP-independent) aquaporin 2 expression and reduce tubular Na+ load, and (4) adding indomethacin to suppress PG production. Option 3 enhances proximal tubular lithium absorption, and thus, it requires lithium dose reduction (by approximately one third) and close monitoring to avoid toxicity. Option 4 is limited by the risk of kidney toxicity. A low-salt diet should always be incorporated. Other agents showing promise include sildenafil, simvastatin, metformin, clopidogrel, PGE2 receptor 4 stimulator (9), and recently, acetazolamide (10). Additional patient-based studies are required before clinical consideration. For our patient, lithium dosing was consolidated, and amiloride was added (10 mg daily). With adjunct low-salt diet, her urine output declined to 3.7 L/d at 1 month follow-up.

Summary

Hypernatremia is common in at-risk populations. Sustained hypernatremia can cause irreversible cell/organ damage and high mortality. Clinical presentations generally reveal the causes and duration of hypernatremia. Copeptin can be useful in diagnosing DI. Cause elimination and correction of [Na+] in a timely fashion by monitoring measured [Na+] are critical.

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2019 by the American Society of Nephrology

References

  1. ↵
    1. Robertson GL
    : Diabetes insipidus: Differential diagnosis and management. Best Pract Res Clin Endocrinol Metab 30: 205–218, 2016
    OpenUrl
  2. ↵
    1. Fenske W,
    2. Refardt J,
    3. Chifu I,
    4. Schnyder I,
    5. Winzeler B,
    6. Drummond J,
    7. Ribeiro-Oliveira A Jr.,
    8. Drescher T,
    9. Bilz S,
    10. Vogt DR,
    11. Malzahn U,
    12. Kroiss M,
    13. Christ E,
    14. Henzen C,
    15. Fischli S,
    16. Tönjes A,
    17. Mueller B,
    18. Schopohl J,
    19. Flitsch J,
    20. Brabant G,
    21. Fassnacht M,
    22. Christ-Crain M
    : A copeptin-based approach in the diagnosis of diabetes insipidus. N Engl J Med 379: 428–439, 2018
    OpenUrlCrossRefPubMed
  3. ↵
    1. Timper K,
    2. Fenske W,
    3. Kühn F,
    4. Frech N,
    5. Arici B,
    6. Rutishauser J,
    7. Kopp P,
    8. Allolio B,
    9. Stettler C,
    10. Müller B,
    11. Katan M,
    12. Christ-Crain M
    : Diagnostic accuracy of copeptin in the differential diagnosis of the polyuria-polydipsia syndrome: A prospective multicenter study. J Clin Endocrinol Metab 100: 2268–2274, 2015
    OpenUrl
  4. ↵
    1. Bolat F,
    2. Oflaz MB,
    3. Güven AS,
    4. Özdemir G,
    5. Alaygut D,
    6. Doğan MT,
    7. Içağasoğlu FD,
    8. Cevit Ö,
    9. Gültekin A
    : What is the safe approach for neonatal hypernatremic dehydration? A retrospective study from a neonatal intensive care unit. Pediatr Emerg Care 29: 808–813, 2013
    OpenUrlCrossRefPubMed
  5. ↵
    1. Alshayeb HM,
    2. Showkat A,
    3. Babar F,
    4. Mangold T,
    5. Wall BM
    : Severe hypernatremia correction rate and mortality in hospitalized patients. Am J Med Sci 341: 356–360, 2011
    OpenUrlCrossRefPubMed
  6. ↵
    1. Borra SI,
    2. Beredo R,
    3. Kleinfeld M
    : Hypernatremia in the aging: Causes, manifestations, and outcome. J Natl Med Assoc 87: 220–224, 1995
    OpenUrlPubMed
  7. ↵
    1. Darmon M,
    2. Pichon M,
    3. Schwebel C,
    4. Ruckly S,
    5. Adrie C,
    6. Haouache H,
    7. Azoulay E,
    8. Bouadma L,
    9. Clec’h C,
    10. Garrouste-Orgeas M,
    11. Souweine B,
    12. Goldgran-Toledano D,
    13. Khallel H,
    14. Argaud L,
    15. Dumenil AS,
    16. Jamali S,
    17. Allaouchiche B,
    18. Zeni F,
    19. Timsit JF
    : Influence of early dysnatremia correction on survival of critically ill patients. Shock 41: 394–399, 2014
    OpenUrlCrossRefPubMed
  8. ↵
    1. Andersen LJ,
    2. Andersen JL,
    3. Pump B,
    4. Bie P
    : Natriuresis induced by mild hypernatremia in humans. Am J Physiol Regul Integr Comp Physiol 282: R1754–R1761, 2002
    OpenUrlCrossRefPubMed
  9. ↵
    1. Sands JM,
    2. Klein JD
    : Physiological insights into novel therapies for nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 311: F1149–F1152, 2016
    OpenUrlCrossRefPubMed
  10. ↵
    1. Gordon CE,
    2. Vantzelfde S,
    3. Francis JM
    : Acetazolamide in lithium-induced nephrogenic diabetes insipidus. N Engl J Med 375: 2008–2009, 2016
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 14 (3)
Clinical Journal of the American Society of Nephrology
Vol. 14, Issue 3
March 07, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Hypernatremia
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hypernatremia
Qi Qian
CJASN Mar 2019, 14 (3) 432-434; DOI: 10.2215/CJN.12141018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Hypernatremia
Qi Qian
CJASN Mar 2019, 14 (3) 432-434; DOI: 10.2215/CJN.12141018
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Introduction
    • Patient 1
    • Patient 2
    • Serum [Na+] Regulation and Pathophysiology of Hyperosmolality
    • Lithium-Induced Nephrogenic DI
    • Diagnosis and Treatment
    • Summary
    • Disclosures
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • The Transition of a Pediatric Kidney Transplant Recipient from Childhood to Adult Care
  • Syndromes of Pseudo-Hyperaldosteronism
  • How I Treat Complement-Mediated TMA
Show more Kidney Case Conference: How I Treat

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • hypernatremia
  • water regulation
  • sodium regulation
  • pathophysiology
  • diagnosis
  • treatment
  • sodium
  • potassium
  • Dehydration
  • diabetes insipidus
  • Ions
  • Acids
  • Noncarboxylic

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire